Skip to main content
Clinical Trials/EUCTR2020-004723-17-BE
EUCTR2020-004723-17-BE
Active, not recruiting
Phase 1

Clinical usefulness and influence on oesophageal motility of pyridostigminefor dysphagia in systemic sclerosis. - PySys

Z Brussel0 sites25 target enrollmentJanuary 18, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Dysphagia by patients suffering from systemic sclerosis
Sponsor
Z Brussel
Enrollment
25
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 18, 2021
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Z Brussel

Eligibility Criteria

Inclusion Criteria

  • \- Patients aged 18 years or older;
  • \- Known systemic sclerosis;
  • \- Dysphagia with Eckardt score 5 or more despite twice daily high dose
  • PPI (omeprazole 40 mg b.i.d., esomeprazole 20 mg b.i.d., pantoprazole
  • 40 mg b.i.d., lansoprazole 30 mg b.i.d.).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 25
  • F.1\.3 Elderly (\>\=65 years) no

Exclusion Criteria

  • \- Presence of reflux oesophagitis grade C or more, eosinophilic
  • oesophagitis, organic stenosis (whether peptic or malignant);
  • \- Prior oesophageal surgery, endoscopic resections, Radiofre\-quency
  • Ablation for Barrett's mucosa or POEM;
  • \- Prior gastric surgery;
  • \- Prior diagnosis of major oesophageal motor disorder such as
  • oesophageal spasm, achalasia, EGJ(esophagogastric junction) outflow
  • obstruction
  • Prevention of major side effects by exclusion of certain patient groups:
  • \- Diarrhoea (defined as Bristol Stool Scale \> 5\) for more than 2 days

Outcomes

Primary Outcomes

Not specified

Similar Trials